CME

Faculty: Christophe Le Tourneau, MD, PhD

Faculty: Marc Oliva, MD, PhD

This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical trials, including KEYNOTE-689 and NIVOPOSTOP. The discussions highlight treatment selection, multidisciplinary coordination among surgical, medical, and radiation oncology teams, and practical considerations such as PD-L1 testing, radiologic assessment, and management of immune-related adverse events. Through expert commentary and a patient case, the program explores strategies for incorporating perioperative immunotherapy into clinical practice and identifying appropriate candidates for this treatment approach.

Faculty: Christophe Le Tourneau, MD, PhD

Faculty: Marc Oliva, MD, PhD

This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical trials, including KEYNOTE-689 and NIVOPOSTOP. The discussions highlight treatment selection, multidisciplinary coordination among surgical, medical, and radiation oncology teams, and practical considerations such as PD-L1 testing, radiologic assessment, and management of immune-related adverse events. Through expert commentary and a patient case, the program explores strategies for incorporating perioperative immunotherapy into clinical practice and identifying appropriate candidates for this treatment approach.

Faculty: Christophe Le Tourneau, MD, PhD

Faculty: Marc Oliva, MD, PhD

This educational series examines the evolving role of perioperative immunotherapy in resectable, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Drs. Le Tourneu and Oliva review the scientific rationale for integrating immune checkpoint inhibitors before and after surgery and discuss emerging evidence from key clinical trials, including KEYNOTE-689 and NIVOPOSTOP. The discussions highlight treatment selection, multidisciplinary coordination among surgical, medical, and radiation oncology teams, and practical considerations such as PD-L1 testing, radiologic assessment, and management of immune-related adverse events. Through expert commentary and a patient case, the program explores strategies for incorporating perioperative immunotherapy into clinical practice and identifying appropriate candidates for this treatment approach.

Faculty: Aditya Bardia, MD, MPH, FASCO

Faculty: Erica L. Mayer, MD, MPH

Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

Faculty: Linda Stein Gold, MD

Faculty: Lakshi Aldredge, MSN, ANP-BC

Faculty: Najat M. Watch, PA

Psoriasis management often begins with topical therapies, phototherapy, or established biologics before escalation. This Broadcast Replay examines earlier biologic use and the role of oral IL-23 receptor antagonists, reviewing the efficacy and safety data, as well as practical considerations including patient selection. Case discussions reinforce key concepts to support individualized treatment decisions for moderate to severe psoriasis, including for those patients who prefer oral therapy or have challenges with injectable options.

Faculty: Scott T. Tagawa, MD, MS

Faculty: Mary-Ellen Taplin, MD

This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: Scott T. Tagawa, MD, MS

Faculty: Mary-Ellen Taplin, MD

This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: Scott T. Tagawa, MD, MS

Faculty: Mary-Ellen Taplin, MD

This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: Scott T. Tagawa, MD, MS

Faculty: Mary-Ellen Taplin, MD

This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, metastatic distribution, comorbidities, and patient goals inform individualized treatment selection. The program reviews key clinical trial evidence, the evolving role of germline and somatic testing, PTEN loss and AKT pathway targeting, and multidisciplinary strategies to manage adverse events and support quality of life during therapy.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 1.00.

Faculty: Payal Kenia Gu, MD

Faculty: Edward Dabrowski, MD

This MinuteCE activity examines the diagnosis and longitudinal management of Rett syndrome across pediatric and adult populations. Faculty experts discuss classic and atypical clinical presentations, differential diagnosis, and the role of genetic testing in supporting accurate diagnosis and earlier recognition. The series also reviews individualized multidisciplinary management strategies, including seizure control, nutritional and respiratory support, rehabilitation therapies, communication approaches, orthopedic surveillance, and behavioral health considerations. Additional discussions address the integration of trofinetide into care plans, transition to adult care, reproductive health, care coordination, and caregiver support across the lifespan.